These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 24583797)
1. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Ok CY; Li L; Xu-Monette ZY; Visco C; Tzankov A; Manyam GC; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Chen J; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ai W; Ponzoni M; Ferreri AJ; Farnen JP; Møller MB; Bueso-Ramos CE; Miranda RN; Winter JN; Piris MA; Medeiros LJ; Young KH Clin Cancer Res; 2014 May; 20(9):2338-49. PubMed ID: 24583797 [TBL] [Abstract][Full Text] [Related]
2. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases. Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Sato A; Nakamura N; Kojima M; Ohmachi K; Carreras J; Kikuti YY; Numata H; Ohgiya D; Tazume K; Amaki J; Moriuchi M; Miyamoto M; Aoyama Y; Kawai H; Ichiki A; Hara R; Kawada H; Ogawa Y; Ando K Cancer Sci; 2014 Sep; 105(9):1170-5. PubMed ID: 24974976 [TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey. Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928 [TBL] [Abstract][Full Text] [Related]
5. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685 [TBL] [Abstract][Full Text] [Related]
6. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832 [TBL] [Abstract][Full Text] [Related]
7. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Tisi MC; Cupelli E; Santangelo R; Maiolo E; Alma E; Giachelia M; Martini M; Bellesi S; D'Alò F; Voso MT; Pompili M; Leone G; Larocca LM; Hohaus S Leuk Lymphoma; 2016; 57(3):628-34. PubMed ID: 26458141 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. Ahn JS; Yang DH; Duk Choi Y; Jung SH; Yhim HY; Kwak JY; Sung Park H; Shin MG; Kim YK; Kim HJ; Lee JJ Am J Hematol; 2013 Sep; 88(9):774-9. PubMed ID: 23760676 [TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update. Hong JY; Ko YH; Kim SJ; Kim WS Curr Opin Oncol; 2015 Sep; 27(5):392-8. PubMed ID: 26258272 [TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly]. Xu FP; Liu YH; Zhuang HG; Luo DL; Li L; Zhang F; Luo XL; Du X; Li WY; Chen Q Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):616-21. PubMed ID: 22177246 [TBL] [Abstract][Full Text] [Related]
11. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Slack GW; Steidl C; Sehn LH; Gascoyne RD Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752 [TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. Kato H; Karube K; Yamamoto K; Takizawa J; Tsuzuki S; Yatabe Y; Kanda T; Katayama M; Ozawa Y; Ishitsuka K; Okamoto M; Kinoshita T; Ohshima K; Nakamura S; Morishima Y; Seto M Cancer Sci; 2014 May; 105(5):537-44. PubMed ID: 24581222 [TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis. Song CG; Huang JJ; Li YJ; Xia Y; Wang Y; Bi XW; Jiang WQ; Huang HQ; Lin TY; Li ZM PLoS One; 2015; 10(7):e0133973. PubMed ID: 26222726 [TBL] [Abstract][Full Text] [Related]
14. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151 [TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154 [TBL] [Abstract][Full Text] [Related]
17. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Beltran BE; Quiñones P; Morales D; Malaga JM; Chavez JC; Sotomayor EM; Castillo JJ Hematol Oncol; 2018 Feb; 36(1):93-97. PubMed ID: 28639256 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features and prognostic significance of CD30 expression in Salas MQ; Climent F; Tapia G; DomingoDomènech E; Mercadal S; Oliveira AC; Aguilera C; Olga G; Moreno Velázquez M; Andrade-Campos M; Encuentra M; Fernández de Sevilla A; Sureda A; Sancho JM; González-Barca E Biomarkers; 2020 Feb; 25(1):69-75. PubMed ID: 31752540 [No Abstract] [Full Text] [Related]
19. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205 [TBL] [Abstract][Full Text] [Related]
20. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]